Trevi Therapeutics, Inc. (TRVI)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $2.35B
- P/E ratio
- —
- EPS
- —
- Volume
- 2,839,784
- 52-week high
- —
- 52-week low
- —
- Open
- $19.28
- Day high
- $19.37
- Day low
- $16.62
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$42.76M | -$0.32 |
| 2024 | — | -$47.91M | -$0.47 |
| 2023 | — | -$29.07M | -$0.29 |
| 2022 | — | -$29.15M | -$0.45 |
| 2021 | — | -$33.94M | -$1.49 |
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
- CEO
- Jennifer L. Good
- Employees
- 34
- Country
- US
- IPO date
- May 7, 2019
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Trevi Therapeutics, Inc.'s stock price today?
- TRVI is trading at $16.77 as of Jul 20, 2026.
- What is Trevi Therapeutics, Inc.'s market cap?
- Trevi Therapeutics, Inc. (TRVI) has a market capitalization of $2.35B.
- Does Trevi Therapeutics, Inc. pay a dividend?
- Trevi Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Trevi Therapeutics, Inc. in?
- Trevi Therapeutics, Inc. operates in the Healthcare sector.